Related Experiment Video
Updated: Jun 4, 2026

Rapid Generation of Amyloid from Native Proteins In vitro
Published on: December 5, 2013
[Amyloidosis in rheumatic diseases]
1Katedra i Klinika Chorób Wewnetrznych, Chorób Tkanki Łacznej i Geriatrii Gdańskiego Uniwersytetu Medycznego ul. Debinki 7, 80-211 Gdańsk.
Abstract:
Amyloidoses represent an inhomogeneous group of diseases characterized by extracellular deposition of amyloid fibrils. AA amyloidosis is a serious life-threatening complication of chronic rheumatic diseases responsible for increased mortality due to organ failure or infection. The main component of amyloid is the serum amyloid A precursor protein (SAA) produced by the liver as an acute phase protein. This article presents the pathogenesis of amyloidosis, which is at the core of our understanding of treatment options. Effective anti-inflammatory therapy of rheumatic diseases is the best way to prevent AA amyloidosis. Early detection of this complication leads to treatment that can effectively retard the course of the disease and may even be accompanied by regression of amyloid deposits. New hope is offered by anti-TNF-alpha antibodies or by eprodisate, which blocks the proamyloidogenic interactions of glycosaminoglycans with SAA.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Cardiomyopathy IV: Restrictive Cardiomyopathy
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management